ArticleCancer discovery2021
Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy.
Open access · hybridAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers.
0numbers the graph read from it
0cells of the map it votes in
118citing papers in PubMed
20.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
118 citing papers in PubMed, 227 citations in OpenAlex.
- Chronic inflammation-responsive hydrogel restores myeloid-T cell crosstalk to reinvigorate antitumor immunity against metastatic colorectal cancer.Bioactive materials · 2026Article
- Regulation of immune checkpoint molecules in cancer immune evasion and therapy.Nature reviews. Cancer · 2026Review
- An immunogenomic classification of solid tumours reveals subtype-specific therapeutic vulnerabilities for immunotherapy.EBioMedicine · 2026Article
- CXCR3 signaling promotes Delta One T cell recruitment and antitumor efficacy in colorectal cancer.Journal for immunotherapy of cancer · 2026Article
- A MOF-in-MOF nanoplatform for photothermal/chemodynamic therapy that enhances antitumor immunity through targeted suppression of the COX-2/PGE2 axis.Journal of nanobiotechnology · 2026Article
- C-type lectin domain family 5 member A-mediated activation of macrophages via a bispecific antibody enhances anti-HER2 therapy.Journal for immunotherapy of cancer · 2026Article
- Breast cancer immunotherapy: mechanisms of immune evasion, biomarkers, and emerging therapeutic strategies.Molecular cancer · 2026Review
- Ablation of prostaglandin ENature biomedical engineering · 2026Article
- A multifunctional hydrogel for obesity-associated tumor immunotherapy and postsurgical wound healing promotion.Bioactive materials · 2026Article
- Prostaglandin ECell death & disease · 2026Article
- Cancer neuroscience: signaling pathways and new therapeutic strategies for cancer.Signal transduction and targeted therapy · 2026Review
- CRISP3, a Potential Tumor Suppressor, Inhibits the Progression of High-Grade Serous Ovarian Carcinoma by Modulating the PI3K/AKT Pathway.Biomedicines · 2026Article
- Genome-wide CRISPR Screening Reveals a PKA-Driven Resistance Mechanism to Metformin for Oral Cancer Prevention That Can Be Exploited by Combination with NSAIDs.Cancer prevention research (Philadelphia, Pa.) · 2026Article
- Identification of the key immune and inflammatory related gene CALCRL as diagnostic biomarker in differentiating uterine leiomyosarcoma from leiomyoma.Frontiers in cell and developmental biology · 2026Article
- Immunosuppressive cells as barriers to cancer therapy: mechanisms and emerging solutions.Frontiers in immunology · 2026Review
- Harnessing human immune system models to validate NADPH oxidase 1 inhibition as treatment for hepatocellular carcinoma.Frontiers in pharmacology · 2026Article
- Stem-like T cells: molecular regulation, functional diversity, and therapeutic implications across diseases.Journal of translational medicine · 2025Review
- A self-delivery albumin nanomedicine amplified photodynamic therapy against esophageal cancer through COX-2/PGE2 interruption and regulation of mitochondrial respiratory.International journal of pharmaceutics: X · 2025Article
- Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges.Signal transduction and targeted therapy · 2025Review
- Treatment outcome and safety of durvalumab after concurrent chemoradiation in very elderly patients with unresectable stage III non-small cell lung cancer.Translational lung cancer research · 2025Article
58 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
15 authors at 2 institutions in 2 countries.
Victoria S Pelly *Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, United Kingdom.
Agrin Moeini *Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, United Kingdom.
Lisanne M RoelofsenDivison of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0001-7686-1614
Eduardo BonavitaCancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, United Kingdom.ORCID 0000-0003-2335-5827
Charlotte R BellCancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, United Kingdom.ORCID 0000-0001-8653-2291
Colin HuttonSystems Oncology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, United Kingdom.ORCID 0000-0003-2254-1038
Adrian Blanco-GomezSystems Oncology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, United Kingdom.ORCID 0000-0002-1956-088X
Antonia BanyardFlow Cytometry, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, United Kingdom.
Christian P BromleyCancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, United Kingdom.ORCID 0000-0001-6203-6891
Eimear FlanaganCancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, United Kingdom.
Shih-Chieh ChiangCancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, United Kingdom.
Claus JørgensenSystems Oncology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, United Kingdom.ORCID 0000-0002-7841-943X
Ton N SchumacherDivision of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0003-0517-8804
Daniela S ThommenDivison of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0002-7431-2854
Santiago ZelenayCancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, United Kingdom. Santiago.Zelenay@cruk.manchester.ac.uk.ORCID 0000-0002-6865-3978
Cancer Research UK Manchester Institute · GBOncode Institute · NL
Funding
Cancer Research UK 12905Cancer Research UK 19258Cancer Research UK 22255Cancer Research UK A19258Cancer Research UK A22255
Abstract
Identifying strategies to improve the efficacy of immune checkpoint blockade (ICB) remains a major clinical need. Here, we show that therapeutically targeting the COX2/PGE
Indexed as
AnimalsAnti-Inflammatory AgentsCell Line, TumorDisease Models, AnimalDrug Therapy, CombinationHumansImmune Checkpoint InhibitorsMiceNeoplasmsTumor MicroenvironmentAnti-Inflammatory AgentsImmune Checkpoint Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.